Acusphere AI-700 Imaging Agent Phase III Protocols Expected By Early 2002
This article was originally published in The Gray Sheet
Executive Summary
Acusphere plans to submit Phase III protocols for its ultrasound contrast agent AI-700 to FDA by early 2002.